Vanguard Group’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98.8M | Buy |
7,049,099
+231,021
| +3% | +$3.24M | ﹤0.01% | 1834 |
|
|
2025
Q1 | $107M | Buy |
6,818,078
+377,363
| +6% | +$5.9M | ﹤0.01% | 1767 |
|
|
2024
Q4 | $89.7M | Sell |
6,440,715
-521,920
| -7% | -$7.27M | ﹤0.01% | 1920 |
|
|
2024
Q3 | $64.8M | Buy |
6,962,635
+818,345
| +13% | +$7.61M | ﹤0.01% | 2070 |
|
|
2024
Q2 | $57.1M | Buy |
6,144,290
+977,873
| +19% | +$9.09M | ﹤0.01% | 2097 |
|
|
2024
Q1 | $51.2M | Buy |
5,166,417
+269,904
| +6% | +$2.67M | ﹤0.01% | 2156 |
|
|
2023
Q4 | $15.8M | Buy |
4,896,513
+2,017,053
| +70% | +$6.52M | ﹤0.01% | 2698 |
|
|
2023
Q3 | $15.3M | Buy |
2,879,460
+229,072
| +9% | +$1.22M | ﹤0.01% | 2662 |
|
|
2023
Q2 | $25.3M | Buy |
2,650,388
+68,257
| +3% | +$650K | ﹤0.01% | 2496 |
|
|
2023
Q1 | $28.4M | Buy |
2,582,131
+50,719
| +2% | +$558K | ﹤0.01% | 2440 |
|
|
2022
Q4 | $37.5M | Buy |
2,531,412
+278,473
| +12% | +$4.12M | ﹤0.01% | 2327 |
|
|
2022
Q3 | $43.1M | Buy |
2,252,939
+454,276
| +25% | +$8.68M | ﹤0.01% | 2257 |
|
|
2022
Q2 | $38.3M | Buy |
1,798,663
+267,565
| +17% | +$5.7M | ﹤0.01% | 2319 |
|
|
2022
Q1 | $29.5M | Buy |
1,531,098
+16,770
| +1% | +$323K | ﹤0.01% | 2570 |
|
|
2021
Q4 | $31.4M | Buy |
1,514,328
+22,121
| +1% | +$459K | ﹤0.01% | 2615 |
|
|
2021
Q3 | $35.6M | Sell |
1,492,207
-2,069
| -0.1% | -$49.4K | ﹤0.01% | 2546 |
|
|
2021
Q2 | $40.8M | Sell |
1,494,276
-35,294
| -2% | -$963K | ﹤0.01% | 2477 |
|
|
2021
Q1 | $44.3M | Buy |
1,529,570
+442,437
| +41% | +$12.8M | ﹤0.01% | 2385 |
|
|
2020
Q4 | $30.6M | Buy |
1,087,133
+229,967
| +27% | +$6.47M | ﹤0.01% | 2436 |
|
|
2020
Q3 | $25.1M | Buy |
857,166
+479,585
| +127% | +$14.1M | ﹤0.01% | 2340 |
|
|
2020
Q2 | $11.4M | Buy |
377,581
+202,173
| +115% | +$6.11M | ﹤0.01% | 2708 |
|
|
2020
Q1 | $5.23M | Buy |
+175,408
| New | +$5.23M | ﹤0.01% | 2954 |
|